On a DART-filed basis, annual revenue rose from KRW 177.3 billion in 2022 to KRW 192.7 billion in 2023 (up 8.6%), KRW 210.9 billion in 2024 (up 9.5%) and KRW 231.8 billion in 2025 (up 9.9%), with growth in three consecutive years from 2023 through 2025.
Operating profit over the same period went from KRW 12.2 billion in 2022 to KRW 9.56 billion in 2023 (down 21.8%) and KRW 2.64 billion in 2024 (down 72.4%), before recovering to KRW 8.47 billion in 2025 (up 220.5%).
The operating margin was 6.9% in 2022, 5.0% in 2023, 1.3% in 2024 and 3.7% in 2025, so margins fell even as revenue grew until the 2025 rebound. Dailypharm reported that 2025 cost of sales reached KRW 111.3 billion, up 16%, and selling, general and administrative expenses reached KRW 97.0 billion, up 11%.
R&D intensity fell from 21.6% of revenue in 2022 to 12.24% in 2024, while third-quarter 2026 selling expenses rose 10.67% year on year to KRW 24.9 billion, with commission fees and market development costs also increasing.
Net income attributable to controlling shareholders went from KRW 5.84 billion in 2022 to a loss of KRW 10.4 billion in 2023, a loss of KRW 10.9 billion in 2024, and a profit of KRW 5.26 billion in 2025. Net income including non-controlling interests, at KRW 12 billion in 2025, is a different figure.
Quarterly operating profit was KRW 5.42 billion in the fourth quarter of 2025, KRW 5.45 billion in the first quarter of 2026, KRW 3.44 billion in the second quarter and KRW 3.55 billion in the third, so the second and third quarters both stayed in the KRW 3 billion range.
The first quarter of 2026 also absorbed a production halt at an overseas contract manufacturer from mid-February to late March for GMP compliance, along with logistics disruption.
The third-quarter 2026 net loss attributable to controlling shareholders of KRW 1.81 billion came after four quarters that totaled KRW 13.4 billion. Operating cash flow fell from KRW 21.8 billion in 2024 to KRW 9.79 billion in 2025.